ClinicalTrials.gg
Active, not recruitingNCT04535193Updated Jul 2, 2026

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

A Phase 1/2 interventional study of 18F-mFBG for intravenous administration in Cardiovascular Diseases, sponsored by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Phase 1/2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.

Read the detailed description

This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation. The first part of the study will examine control subjects, patients with very low likelihood of coronary heart disease. This initial part will determine optimal imaging procedures for studying uptake and clearance of 18F-mFBG in myocardial sympathetic neurons and provide preliminary data for estimating radiation dosimetry in adults and developing reference files for quantification of normal and abnormal levels of the radiopharmaceutical. The second part will examine a group of stable patients with New York Heart Association (NYHA) class 2 heart failure (HF) and reduced left ventricular (LV) systolic function (LV ejection fraction (EF) ≤35%). The primary objectives of the second part will be to:

  • document the degree to which 18F-mFBG uptake in the heart is reduced and
  • characterize the distribution of regional abnormalities in relation to findings on other cardiac imaging studies such as myocardial perfusion (MP) and magnetic resonance (MR) imaging.

Effectiveness of 18F-mFBG will be judged in relation to historical experience with other nuclear imaging agents for cardiac sympathetic innervation imaging such as a 123I-meta-iodobenzylguanidine (mIBG) and 11C-hydroxyephedrine (HED).

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • 18F-mFBG
  • meta-fluorobenzylguanidine
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 10 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age at study entry
  • able and willing to comply with study procedures
  • signed and dated is obtained
  • male or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or hysterectomy), (cessation of menses for more than 1 year), non-lactating, or of for whom the result of a serum pregnancy test performed at screening is negative.

For control subjects:

  • Subject is either:

    • \<40 years old and has a likelihood assessment for CAD \<10%, or
    • 40-50 years old, has a likelihood assessment for CAD \<10%, and a normal stress MPI study or stress echocardiography performed within 6 months before study entry, or
    • Without significant coronary atherosclerotic disease (no arterial stenosis with >30% narrowing) as demonstrated by a coronary angiography performed with 6 months before study entry.

For heart failure subjects:

  • Diagnosed with HF at least 1 year before enrollment.
  • HF classification Class II at enrollment.
  • Rest (LVEF) ≤35% measured by an appropriate method (e.g., radionuclide or contrast ventriculography, -gated SPECT MPI, or echocardiography) within 180 days prior to the study imaging procedure, with no change in clinical condition since the LVEF measurement.
  • Primary prevention ICD, implanted at least 6 months before enrollment.
  • Clinically stable for at least 30 days before enrollment (e.g., not experiencing continuing chest pain, hemodynamic instability, or arrhythmia (including ICD discharge)) and remains stable to the time of the study imaging procedure.

Exclusion criteria

Exclusion Criteria:

  • Previously entered into this study or has participated in any other medicinal product or medical device study within 30 days of enrollment.
  • History or suspicion of significant allergic reaction or anaphylaxis to any components of the 18F-mFBG imaging agent.
  • Ventricular pacemaker that routinely functions (>5% paced beats)
  • Cardiac revascularization (e.g., percutaneous transluminal coronary angioplasty, PCI, or CABG), or an acute myocardial infarction within the past 30 days.
  • Presents with any other clinically active, serious, life-threatening disease with a of less than 1 year or where participation in the study might compromise the management of the subject or other reason that in the judgment of the investigator(s) makes the subject unsuitable for participation in the study.
  • Serious non-cardiac medical condition associated with significant elevation of plasma catecholamines including pheochromocytoma.
  • Claustrophobic or has a movement disorder that prevents him/her from lying still in a supine position for up to an hour at a time.
  • Renal insufficiency (serum creatinine >3.0 mg/dL).
  • Use of medications that are known to interfere with uptake of NET-dependent agents and these medications cannot be safely withheld 24 hours before study procedures.
  • Participated in a research study using ionizing radiation in the previous 12 months.
  • For control subjects: a history of Type I or Type II Diabetes Mellitus, signs/symptoms of neurological disease (e.g., Parkinson's Disease, Multiple System Atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic nervous system.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Other
    Low likelihood of coronary heart disease

    Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration.

    Drug: 18F-mFBG for intravenous administration

  • Other
    Heart Failure + left ventricular function (LVEF ≤ 35%)

    Thorax and total body imaging for quantification of myocardial sympathetic innervation. PET imaging to 100 minutes post-administration

    Drug: 18F-mFBG for intravenous administration

Interventions

  • DrugFlorbenguane F-18Studies of Florbenguane F-18Florbenguane F-18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent

    Also known as: meta-fluorobenzylguanidine, IRP101

06

What researchers measure

Primary outcomes

  1. Chang in 18F-mFBG uptake

    Change in 18F-mFBG uptake in the total body and the normal heart over time (based on serial PET images) to: * document the time course of global and regional myocardial activity reflecting specific uptake and clearance of the radiopharmaceutical; * estimate individual organ and whole-body radiation dosimetry.

    Time frame: Up to 210 minutes after dosing

  2. Evaluation of 18F-mFBG for imaging myocardial sympathetic innervation

    To demonstrate the extent and degree of global and regional reduced 18F-mFBG myocardial uptake on PET/CT (or PET/MR) of HF subjects with significant LV dysfunction (LVEF≤35%).

    Time frame: Up to 100 minutes after dosing

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Mar 2025, 40 months.

Of 20 phase 1/2 interventional studies under Cardiovascular Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 62. This study's 40 months is close to that.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Sep 1, 2020
StartActual
Nov 5, 2021
Primary completionActual
Mar 7, 2025
CompletionEst.
Aug 30, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04535193
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Collaborators
Mount Sinai Hospital, New York
Responsible party
Sponsor
First posted
Sep 1, 2020
Start date
Nov 5, 2021
Primary completion
Mar 7, 2025
Completion
Aug 30, 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

Vikram Agarwal, MD
principal investigator · Mount Sinai Morningside

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbenguane F-18

Start the discussion